Last reviewed · How we verify
Anti-TNF Drug
Anti-TNF Drug is a TNF-alpha inhibitor Small molecule drug developed by Schneider Children's Medical Center, Israel. It is currently in Phase 2 development for Rheumatoid arthritis, Psoriatic arthritis, Plaque psoriasis. Also known as: Remicade, Remsima, Humira.
Anti-TNF drugs block the action of tumor necrosis factor-alpha (TNF-alpha), a protein involved in systemic inflammation.
Anti-TNF drugs block the action of tumor necrosis factor-alpha (TNF-alpha), a protein involved in systemic inflammation. Used for Rheumatoid arthritis, Psoriatic arthritis, Plaque psoriasis.
At a glance
| Generic name | Anti-TNF Drug |
|---|---|
| Also known as | Remicade, Remsima, Humira |
| Sponsor | Schneider Children's Medical Center, Israel |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
TNF-alpha is a cytokine that promotes inflammation and is involved in the pathogenesis of various autoimmune diseases. By blocking TNF-alpha, anti-TNF drugs reduce inflammation and alleviate symptoms in patients with conditions such as rheumatoid arthritis and psoriasis.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Plaque psoriasis
Common side effects
- Injection site reaction
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy (PHASE2, PHASE3)
- Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule (PHASE2)
- Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (PHASE3)
- Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) (PHASE3)
- Association of Erectile Dysfunction With Neuropathic Pain, Disease Activity, and Functional Status in Male Patients With Axial Spondyloarthritis: A Cross-Sectional Observational Study
- Deucravacitinib-TNF Combination Therapy for Difficult-to-Control Psoriatic Disease (PHASE4)
- Stand UP to Rheumatoid Arthritis (SUPRA) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-TNF Drug CI brief — competitive landscape report
- Anti-TNF Drug updates RSS · CI watch RSS
- Schneider Children's Medical Center, Israel portfolio CI
Frequently asked questions about Anti-TNF Drug
What is Anti-TNF Drug?
How does Anti-TNF Drug work?
What is Anti-TNF Drug used for?
Who makes Anti-TNF Drug?
Is Anti-TNF Drug also known as anything else?
What drug class is Anti-TNF Drug in?
What development phase is Anti-TNF Drug in?
What are the side effects of Anti-TNF Drug?
What does Anti-TNF Drug target?
Related
- Drug class: All TNF-alpha inhibitor drugs
- Target: All drugs targeting TNF-alpha
- Manufacturer: Schneider Children's Medical Center, Israel — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Psoriatic arthritis
- Indication: Drugs for Plaque psoriasis
- Also known as: Remicade, Remsima, Humira
- Compare: Anti-TNF Drug vs similar drugs
- Pricing: Anti-TNF Drug cost, discount & access